PMID- 24033707
OWN - NLM
STAT- MEDLINE
DCOM- 20150302
LR  - 20240321
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 77
IP  - 6
DP  - 2014 Jun
TI  - The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer 
      therapy.
PG  - 917-28
LID - 10.1111/bcp.12228 [doi]
AB  - AIM(S): Insulin-like growth factor-1 receptor (IGF-1R) targeted therapies have 
      become one of the intriguing areas in anticancer drug development during the last 
      decade. As one of these therapies, anti-IGF-1R monoclonal antibodies (mAbs) are 
      also advancing further in development. Our purpose was to conduct a systematic 
      review of the adverse events (AEs) caused by anti-IGF-1R monoclonal antibodies in 
      cancer therapy. METHODS: We searched the term'IGF-1R monoclonal antibody' in the 
      Pubmed database and found 389 related articles. After elaborate selection, 15 
      clinical studies that satisfied our criteria were then adopted for further 
      analysis. We extracted all the useful information about the AEs of mAbs from the 
      enrolled studies. Every kind of reported AE as well as corresponding incidences 
      were summed up and calculated. We compared AE incidence differences in two age 
      groups, and analyzed toxicities of mAbs used as a single agent or combined with 
      chemotherapies. Finally, the differences of AE profiles between individual mAbs 
      were also valued. RESULTS: AEs were more severe in the lower age group and 13 of 
      19 AE incidences in the single-agent group were significantly lower than in the 
      combination group (P < 0.05). R1507 seemed to show a worse AE profile than 
      cixutumumab and figitumumab. CONCLUSIONS: When anti-IGF-1R mAbs are used for 
      cancer therapy, it is essential to choose the proper drug and combined 
      chemotherapies to reduce AE occurrences. Also, administration of these mAbs to 
      younger patients should be more carefully supervised. Furthermore, some more 
      frequently observed AEs for specific mAb should be paid adequate attention.
CI  - (c) 2013 The British Pharmacological Society.
FAU - Ma, Honghai
AU  - Ma H
AD  - Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong 
      University, Shandong University, Jinan, China.
FAU - Zhang, Tiehong
AU  - Zhang T
FAU - Shen, Hongchang
AU  - Shen H
FAU - Cao, Hongxin
AU  - Cao H
FAU - Du, Jiajun
AU  - Du J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2285XW22DR (cixutumumab)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - VE267FC2UB (figitumumab)
RN  - Y64GQ0KC0A (teprotumumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Cardiotoxicity/etiology
MH  - Humans
MH  - Hyperglycemia/chemically induced
MH  - Neoplasms/*drug therapy
MH  - Neutropenia/chemically induced
MH  - Receptor, IGF Type 1/*immunology
MH  - Thrombocytopenia/chemically induced
PMC - PMC4093917
OTO - NOTNLM
OT  - R1507
OT  - adverse events
OT  - anti-IGF-1R monoclonal antibody
OT  - cixutumumab
OT  - dalotuzumab
OT  - figitumumab
EDAT- 2013/09/17 06:00
MHDA- 2015/03/03 06:00
PMCR- 2015/06/01
CRDT- 2013/09/17 06:00
PHST- 2012/10/19 00:00 [received]
PHST- 2013/08/11 00:00 [accepted]
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2015/03/03 06:00 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - 10.1111/bcp.12228 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2014 Jun;77(6):917-28. doi: 10.1111/bcp.12228.